NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy
Public ClinicalTrials.gov record NCT03589339. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase I Dose Escalation / Dose Expansion Study of NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The 1100 study is an open-label, Phase I, dose escalation and expansion prospective clinical study to assess the safety of intratumoral injection of NBTXR3 activated by radiotherapy in combination with anti-PD-1 therapy.
Study identification
- NCT ID
- NCT03589339
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 145 participants
Conditions and interventions
Conditions
- Radiotherapy
- Immunotherapy
- Microsatellite Instability-High Solid Malignant Tumour
- Metastasis From Malignant Tumor of Liver
- Squamous Cell Carcinoma of Head and Neck
- Metastasis From Malignant Tumor of Cervix
- Metastatic Renal Cell Carcinoma
- Metastasis From Malignant Melanoma of Skin (Disorder)
- Metastatic Triple-Negative Breast Carcinoma
- Metastatic NSCLC
- Metastasis From Malignant Tumor of Bladder (Disorder)
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 16, 2019 (Actual)
- Primary completion
- Apr 30, 2027 (Estimated)
- Completion
- Aug 30, 2027 (Estimated)
- Last update posted
- Oct 24, 2025
2019 – 2027
United States locations
- U.S. sites
- 13
- U.S. states
- 12
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of California San Francisco | San Francisco | California | 94158 | — |
| Moffitt Cancer Center | Tampa | Florida | 33612 | — |
| Emory University | Atlanta | Georgia | 30308 | — |
| University of Chicago Medical Center | Chicago | Illinois | 60637 | — |
| Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center | Baltimore | Maryland | 21287 | — |
| Karmanos Cancer Institute | Detroit | Michigan | 48201 | — |
| Henry Ford Cancer Institute | Detroit | Michigan | 48202 | — |
| Christus St. Vincent Regional Cancer Center | Santa Fe | New Mexico | 87505 | — |
| Northwell Health | Manhasset | New York | 11030 | — |
| University of North Carolina, School of Medicine | Chapel Hill | North Carolina | 27516 | — |
| Gabrail Cancer Center | Canton | Ohio | 44718 | — |
| St Luke's University Health Network | Bethlehem | Pennsylvania | 18015 | — |
| Sanford Cancer Center | Sioux Falls | South Dakota | 57104 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03589339, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 24, 2025 · Synced Oct 18, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT03589339 live on ClinicalTrials.gov.